About AnadysAnadys Pharmaceuticals.

Anadys ‘ clinical development programs include ANA975 for the treatment of HCV and HBV and ANA380 for the treatment of HBV. In addition, Anadys ‘ therapeutic platform developed for. Strong and continual pipeline of drug candidates in clinical development About LG Life Sciences.. About AnadysAnadys Pharmaceuticals, a biopharmaceutical company, is to the advancement of patient care through the discovery LGLS of novel small molecule drugs for the treatment of hepatitis, other serious infections and cancer. The Company has core expertise in Toll-Like Receptor – coupled based small molecule therapeutics and structure – based drug design using medicinal chemistry.

The research was supported by a National Institutes of Health grant and also grants from the U.S. Department of Defense, Army Research Office, Penn Genome Frontiers Institute, Nano – Bio Interface Center at Penn, Nanotechnology Institute of the Commonwealth of Pennsylvania and Pennsylvania supports Department of Health. The Department of Health disclaims responsibility for any analyzes, interpretations or conclusions.Each of said KRX to-0401 Phase 3 programs shall be conducted under Special Protocol Assessment agreement with the FDA. The risk that Zerenex , an oral , iron -based compound. The capacity to phosphates and phosphate and non-resorbable shape Complex The Phase 3 clinical Programme Zerenex in the treatment of the control of hyperphosphataemia for patients with end-stage renal disease is carried out according in order. One SPA is agreement with the FDA Keryx is in NYC.. KRX to-0401 in a license for Keryx out of Aeterna Zentaris Inc. the United States, Canada and Mexico.

Keryx Biopharmaceuticals is concentrated on acquisition, develop and market medically relevant pharmaceuticals for the treatment of life-threatening illnesses such as cancer and kidney disease.

Out of 38 patients who have at the stage II trials been 27 patients, the regimes previous the refractory based about of a 5-FU. Surgery is often randomized phase 3 double-blind study to compare perifosine+ capecitabine vs. Placebo+ capecitabine into 5-FU refractory patient with a advanced refractory colorectal cancer under a Special Protocol Assessment by FDA is admitted to hospital enrolling patients at multiple centers in the U.S.